We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In this episode of ETF Spotlight, I talked with Brad Loncar, CEO of Loncar Investments, who created the Loncar Cancer Immunotherapy Index, the underlying benchmark for the Loncar Cancer Immunotherapy ETF (CNCR - Free Report) .
Immunotherapy is often called a game-changer in treating cancer. Many encouraging advances have been made in this area and that’s why healthcare companies are investing billions of dollars in this field.
In simple words, immunotherapy uses the body’s immune system to fight cancer.
Brad explained the basics of immunotherapy, and why this therapy is often called the next revolution in cancer treatment. In certain types of cancers, immunotherapy could be more effective than traditional cancer treatments like chemotherapy.
There’s a lot of innovation going on in this space. However, most investors are not aware of this promising space within the biotechnology sector.
And, immunotherapy is not just one thing. Brad talked about the different types of immunotherapy treatments like checkpoint inhibitors, vaccines and cell therapy.
Some of these treatments and drugs have already been approved by the FDA and are on the market.
We also discussed which types of cancer are being treated with immunotherapy and how this treatment works better in certain types of cancers.
We then talked about the Cancer Immunotherapy Index that tracks a basket of companies at the forefront of immunotherapy research.
I noted that the index constituents include some large diversified biotech companies and many smaller pure-play companies that are focused on immunotherapy and cancer research.
Brad explained how companies are selected for inclusion in the index.
Loncar Investments has also partnered with the Cancer Research Institute (CRI) and donates regular contributions to CRI that amount to 4 basis points of the ETF’s total assets.
Launched on March 18, 2015, the Loncar Cancer Immunotherapy ETF (CNCR - Free Report) has 30 holdings, which are equally weighted. The expense ratio is 79 basis points.
The ETF is one of the best performing ETFs this year—up about 30%. What are the drivers of the excellent performance? Please listen to the podcast to find out.
Brad also highlighted another index he launched recently; it focuses on China biotech sector.
If you want to learn about the immunotherapy index and the ETF, please visit their website loncarfunds.com
Please also visit the Cancer Research Institute to learn about this cancer treatment and clinical trials.
And, please visit the ETF section of zacks.com for more information on this ETF and other ETFs.
Also, make sure to tune in for next podcast on March 22nd. If you have any comments or questions, please email podcast@zacks.com
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's an ETF to Invest in Immunotherapy--the Game Changing Cancer Treatment
In this episode of ETF Spotlight, I talked with Brad Loncar, CEO of Loncar Investments, who created the Loncar Cancer Immunotherapy Index, the underlying benchmark for the Loncar Cancer Immunotherapy ETF (CNCR - Free Report) .
Immunotherapy is often called a game-changer in treating cancer. Many encouraging advances have been made in this area and that’s why healthcare companies are investing billions of dollars in this field.
In simple words, immunotherapy uses the body’s immune system to fight cancer.
Brad explained the basics of immunotherapy, and why this therapy is often called the next revolution in cancer treatment. In certain types of cancers, immunotherapy could be more effective than traditional cancer treatments like chemotherapy.
There’s a lot of innovation going on in this space. However, most investors are not aware of this promising space within the biotechnology sector.
And, immunotherapy is not just one thing. Brad talked about the different types of immunotherapy treatments like checkpoint inhibitors, vaccines and cell therapy.
Some of these treatments and drugs have already been approved by the FDA and are on the market.
We also discussed which types of cancer are being treated with immunotherapy and how this treatment works better in certain types of cancers.
We then talked about the Cancer Immunotherapy Index that tracks a basket of companies at the forefront of immunotherapy research.
I noted that the index constituents include some large diversified biotech companies and many smaller pure-play companies that are focused on immunotherapy and cancer research.
Brad explained how companies are selected for inclusion in the index.
Loncar Investments has also partnered with the Cancer Research Institute (CRI) and donates regular contributions to CRI that amount to 4 basis points of the ETF’s total assets.
Launched on March 18, 2015, the Loncar Cancer Immunotherapy ETF (CNCR - Free Report) has 30 holdings, which are equally weighted. The expense ratio is 79 basis points.
The ETF is one of the best performing ETFs this year—up about 30%. What are the drivers of the excellent performance? Please listen to the podcast to find out.
Brad also highlighted another index he launched recently; it focuses on China biotech sector.
If you want to learn about the immunotherapy index and the ETF, please visit their website loncarfunds.com
Please also visit the Cancer Research Institute to learn about this cancer treatment and clinical trials.
And, please visit the ETF section of zacks.com for more information on this ETF and other ETFs.
Also, make sure to tune in for next podcast on March 22nd. If you have any comments or questions, please email podcast@zacks.com